By William Janes ( June 25, 2025, 3:56 PM BST) -- AstraZeneca on Wednesday sought to reinstate supplementary patent protection for its billion-dollar diabetes drug dapagliflozin, telling a London appeals court that a judge was wrong to rule the patent was invalid....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.